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INTRODUCTION 
 
 Cardiovascular disease is an epidemic of modern society. Type 2 
diabetes mellitus is an epidemic in India for the past few decades. Diabetes 
mellitus is the most important risk factor associated with two to four fold 
increased incidence of coronary artery disease.  
 Nearly 120 years have elapsed since uric acid was first described as a 
potential risk factor in the development of cardiovascular disease1. 
 Hyperuricemia is one of the component of syndrome – X2. Serum uric 
acid is a potential cardiovascular disease risk factor has ballooned in the last 
several years with numerous abstracts and research papers, multiple editorials, 
and review articles.  
 The four major risk factors for CAD viz., hypercholesterolemia, 
hypertension, diabetes mellitus, and cigarette smoking which were present in 
Framingham’s cohort are difficult to explain among Indians with CAD. CAD in 
Indians is present even with low cholesterol level. Obesity, systemic 
hypertension, hypercholesterolemia is associated with NIDDM, as a result of 
insulin resistance state.  
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 Much but not all epidemiological research identifies hyperuricemia is a 
independent risk factor for the development of cardiovascular disease and renal 
disease, particularly patients with hypertension or congestive heart failure and 
in women3.  
 Some have found a significant and specific independent association 
between uric acid level and cardiovascular mortality and morbidity, while 
others have come to an opposite conclusion. Thus despite abundant 
epidemiological evidence, the role of increased serum uric acid and 
cardiovascular risk is controversial.  
 Here an attempt has been made to study the level of serum uric acid in 
type 2 diabetes mellitus and the correlation between elevated serum uric acid 
level and the component of metabolic syndrome like obesity, hypertension, 
dyslipidemia.  
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AIMS AND OBJECTIVES 
 
 
1. To identify the level of uric acid in patients with type 2 diabetes mellitus.  
 
2. To identify whether any association exist between age, sex, 
anthropometric measurements (BMI, WHR), hypertension, dyslipidemia 
and coronary artery disease with serum uric acid level.   
 
 
 
 
 
 
 
 4
 
REVIEW OF LITERATURE 
 
Diabetes mellitus – Type 2  
 The previously used terminology is non insulin dependent diabetes 
mellitus (NIDDM). Type 2 diabetes mellitus begins in the middle age or after 
40 years. It is not uncommon to come across the development of diabetes in 
third decade itself in our country.  
Diagnosis  
   The national diabetes data group (1979) and World Health Organization 
(1985) have issued diagnostic criteria for diabetes mellitus4.  
1. Symptoms of diabetes and random blood sugar concentration                    
≥ 200mg/dl.  
2. Fasting plasma glucose ≥126mg/dl. 
3. 2 hr plasma glucose (postprandial) ≥200mg/dl during an oral glucose 
tolerance test. 
4. IGT - Impaired Glucose Tolerance is present when fasting level is ≤126 
and 2. hr value in the range of 140-200mg/dl.  
5. IFG – Impaired Fasting Glucose when the fasting level is >110 and         
≤126 and 2 hr value is ≤140mg/dL.   
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Table 1:  Diagnostic Criteria for diabetes mellitus 
Category  Fasting p.g 2 hr p.g.  
Normal  <110mg/dl <140mg/dl 
Diabetes  ≥126mg/dl ≥200mg/dl 
IFG 110-125mg/dl - 
IGT - 140-199mg/dl 
 
Importance of IFG and IGT 
 There is no clear consensus (with current evidence) on whether IFG and 
IGT should be classified as disease, but they clearly represent risk factors and 
risk markers for diabetes and CVD, respectively. Both IGT and IFG are 
similarly associated with increased risk of diabetes, but IGT is more strongly 
associated with CVD outcomes. Risks are higher when IFG and IGT coexists. 
Lifestyle interventions are highly effective in delaying or presenting the onset 
of diabetes in people with IGT and may reduce CVD and total mortality.   
Epidemiology  
 The worldwide prevalence of diabetes mellitus has risen dramatically 
over the past two decades. Although the prevalence of both type 1 diabetes 
mellitus, and type 2 diabetes mellitus is expected to rise more rapidly in the 
feature because of increasing obesity and reduced activity levels. In 2000 the 
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prevalence of diabetes mellitus was estimated to be 0.19% in people <20 years 
old, 8.6% in people >20 years old. In individuals >65 years the prevalence of 
diabetes mellitus was 20.1%. The prevalence is similar in men and women 
throughout most age ranges but is slightly greater is men >60 years. The 
prevalence of type 2 diabetes mellitus and its harbinger IGT, is highest in 
Pacific island, intermediate in our country and United States and relatively low 
in Russia and China. This variability is likely due to genetic, behavioural, and 
environmental factors.  
 
 On analysis of the trend in the epidemiology of diabetes, Mccarty and 
Zimmet (1994) have estimated, by projection, the change of prevalence of 
diabetes around the globe by 2010 (Table 2). 
 
 
 
 
 
 
 
 
Table 2:     Estimated of number of Diabetic patients in millions*  
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 Type of 
Diabetes 
1994 2000 2010 
GLOBAL 
IDDM 
NIDDM 
Total 
11.50 
98.90 
110.40 
18.10 
157.30 
175.40 
23.70 
215.60 
239.30 
INDIA 
IDDM 
NIDDM 
Total 
1.80 
15.70 
17.30 
3.31 
28.99 
32.30 
4.70 
42.20 
46.90 
CHINA 
IDDM 
NIDDM 
Total 
0.57 
7.20 
7.77 
1.40 
18.40 
19.80 
2.26 
29.59 
31.85 
USA 
IDDM 
NIDDM 
Total 
1.48 
12.30 
13.78 
1.67 
13.90 
15.57 
1.86 
15.57 
17.43 
JAPAN 
IDDM 
NIDDM 
Total 
0.39 
5.18 
5.57 
0.40 
5.30 
5.70 
0.41 
5.40 
5.81 
 
*Ref: Maccarty and Zimmet (1994) 
 
This table showing High prevalence of Diabetes in India and contributes 
5.08% of Diabetes world wide. Japan has relatively Low incidence of Diabetes. 
Pathogenesis of type 2 diabetes mellitus  
 Insulin resistance and insulin secretion are central to the development of 
type 2 diabetes mellitus.  
1. Beta cell dysfunction  
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 Beta cell dysfunction is the major genetic component contributing to the 
development of type 2 diabetes mellitus5.  The beta cell mass is mildly reduced 
especially when obesity is taken in to account. Type 2 diabetes mellitus is a 
genetically programmed failure of the beta cell to compensate for insulin 
resistance6.  
2. Insulin resistance   
 The variability is insulin response was first documented by Himsworth.    
Who subsequently used glucose insulin sensitivity test to assess individual 
sensitivity to insulin7. Over three decades later, Reaven and coworkers (1966) 
introduced a new method for estimation of insulin mediated glucose uptake by 
peripheral tissues. Further Reaven aroused widespread interest on insulin 
resistance and disorders associated with it through his banting oration of 1987.  
3. Genetic factors  
 Charack, and Susrutha, the ancient Indian physicians who first described 
Madhu Meha (diabetes) had stipulated that the disorder was genetically 
determined and hence incurable.    
 Results from cross sectional and longitudinal studies of families mono 
and dizygotic twins, offspring of diabetic parents both or either sibs and other 
first degree relatives of diabetic probands strongly indicate the genetic basis of 
diabetes8.  
4. Acquired factors  
 9
   Although both impaired beta cell secretion and insulin resistance are 
basically inherited, acquired factors play an important role in the unmasking of 
type 2 diabetes mellitus. They are  
 Beta cell cytotoxic chemical or viruses  
 Autoimmunity  
 Ageing, obesity  
 TNF α, leptin  
 Physical inactivity  
 Diet  
Risk factors for type 2 diabetes mellitus (ADA, 2004)9: 
 Family history of diabetes  
 Obesity BMI >25kg/m2 
 Physical inactivity  
 Previously identified IFG and IGT  
 History of GDM  
 Systemic hypertension (Bp: ≥140/90mmHg) 
 HDL level ≤35mg/dl, TG level ≥250mg/dl  
 Poly cystic ovarian disease or acanthosis nigricans  
 History of vascular disease  
(Source: Adopted form American Diabetes Association (ADA) : 2004) 
Complications of diabetes mellitus  
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Diabetes mellitus 
 
  Acute complications        Chronic complications  
 
 1. Diabetic      Microvascular  macrovascular  
  
      ketoacidosis                         complications  complications  
   
 2. Nonketotic    1. Retinopathy  1. Coronary  
      hyperosmolar coma             artery disease  
 3. Hypoglycemia    2. Neuropathy  2. Peripheral  
 4. Lactic acidosis    3. Nephropathy      vascular  
             disease  
         3. Cerebro  
             vascular  
           disease 
Others   
1. Gastrointestinal –gastroparesis, diarrhea  
2. Genitourinary – uropathy / sexual dysfunction  
3. Dermatological – acanthosis nigricans.  
4. Infections 
5. Cataract  
6. Glaucoma  
 
 
 
INSULIN RESISTANCE 
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Other names 
 Metabolic syndrome  
 Syndrome X  
 Reaven syndrome  
History  
 In 1973, patients with anginapectoris with angiographically normal 
coronary arteries were recognized receiving the label of syndrome X and 
patients with this syndrome were also reported to have hyperinsulinemia.  
 In 1988, Reaven postulated the link between insulin resistance, obesity, 
systemic hypertension and dyslipidemia (high TG, Low HDL) and 
cardiovascular disease.  
 Again in 1993, Reaven gave an expanded definition of syndrome X. 
 In 1989 Kaplan also discussed deadly quartet associated with insulin 
resistance – central obesity, hypertension, impaired glucose tolerance, and 
hypertriglyceridemia.  
 In 1991, Defronzo and Ferraninni discussed the multifaceted nature of 
insulin resistance syndrome. Subsequent addition to the syndrome were small 
dense LDL, increased proinsulin, microalbuminuria and hyperuricemia10.  
 In 1995, Godsland and Steavenson raised the question: Is insulin 
resistance a syndrome or a tendency?11.  
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 In 1995, Yudkin collaborated with Barker’s group to study the 
relationship between low birth weight and glucose and insulin metabolism in 4 
year old urban Indian children, and they told importance to be given to events 
in later life too for the genesis of insulin resistance syndrome. The development 
of cardiovascular risk is an ongoing process and prevention is possible through 
life style modification12.  
 In 1996, Steinberg established that obesity / insulin resistance is 
associated with endothelial dysfunction13.  
In 1997, Marita showed insulin receptor defect in the erythrocytes of 
obese Asian Indian women with acanthosis nigricans and exhibiting impaired 
glucose tolerance14.  
 In 1998, Misra has discussed the current perspective of insulin resistance 
syndrome and its relevance to Indians15.   
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Table 3: Effects Of Insulin Resistance* 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Ref. Godsland IF, Stevenson JC [1995] 
 
 
 
 
Criteria  
INSULIN RESISTANCE 
Increased Increased Increased 
Insulin  
Proinsulin  
PAI - 1 
TG synthesis  
Obesity  
Uric acid  
Small dense LDL 
Sodium water 
retention  
Sympathomimetic 
activity  
(counter regulatory 
response)  
Reduced  Reduced  Reduced  
Vasodilation 
(No mediated) 
HDL Triglyceride 
elimination  from 
circulation level  
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According to ATP III guidelines metabolic syndrome is defined by the 
presence of three of the following:  
 
Table 4: Criteria for metabolic syndrome4: 
No Risk factors Defining level 
1 Abdominal obesity: 
waist  circumference 
>102cm in men  
>88 cm in women  
2 Triglyceride ≥150mg/dL 
3 HDL  
cholesterol  
<40mg/dL in men  
<50mg/dL in women  
4 Blood pressure  ≥130/85mmHg 
5 Fasting plasma glucose  ≥110mg/dL 
  
In addition, following components are also included or expanded in 
metabolic syndrome:  
 Raised apo B 
 HYPERURICEMIA  
 Increased small dense LDL particles  
 Microalbuminuria  
 Increased plasminogen activator inhibitor (PAI – 1) 
 Poly cystic ovarian syndrome  
 Increased fibrinogen    
Types  
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 Two different types of insulin resistance have been described in adults.  
1. Type A: which affects young women and it is characterised by severe 
hyperinsulinemia, obesity, and features of hyperandrogenism. It is due to 
genetic defect in insulin receptor number and function16.  
2. Type B: which affects middle aged women and it is characterised by 
severe hyperinsulinemia, features of hyperandrogenism, and 
autoimmune disorders. It is due to antibodies against insulin receptors17.  
 
 
OBESITY 
 Obesity is an increasing problem in the developed and developing 
countries.  Obesity is a state of excess adipose tissue mass. The distribution of 
adipose tissue in different anatomic depots also has substantial implications for 
morbidity specifically intra abdominal and abdominal subcutaneous fat have 
more significance than subcutaneous fat present in the buttocks and lower 
extremities. This distinction is most easily made by determining the waist hip 
ratio, with a ratio >0.9 in women and >1.0 in men being abnormal.  
 
 
 
Table 5: Classification of Obesity 
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No. Waist hip ratio  Type of obesity  Prognosis  
1 0.8 or less  Pear shaped obesity  Good 
2 0.9 or greater Apple shaped obesity  Bad 
 
Measures to assess obesity  
 Body mass index (BMI) 
 Skin fold thickness 
 Densitometry  
 CT or MRI 
 Electrical impedance   
The most widely used method to assess obesity is body mass index, it 
calculated by using formula.  
BMI = weight (kg)/height2 (m) 
Table 6: Classification of Body Status on BMI 
Classification  BMI Risk of co morbidity  
Underweight  <18.50 Low 
Normal  18.50-24.99 Average 
Overweight  >25.00  
Preobese  25.00-29.99 Increased 
Obese class I 30.00-34.99 Moderate 
Obese class II 35.00-39.99 Severe 
Obese class III >40.00 Very severe  
 
 17
 Body mass index for the midpoint of all heights and frames among both 
men and women range from 19 to 26 kg/m2, at a similar body mass index, 
women have more body fat than men. Based on unequivocal data of substantial 
morbidity, a body mass index of 30 is most commonly used as a threshold for 
obesity in both men and women. Large scale epidemiological studies suggest, 
that all cause, metabolic, cancer, and cardiovascular morbidity begin to rise 
when body mass index are ≥25, suggesting that the cut off for obesity should be 
lowered. A body mass index between 25 to 30 should be viewed as medically 
significant and worthy of therapeutic intervention, especially in the presence of 
other risk factors such as hypertension, glucose intolerance.    
Table 7: Relative risk of health problems associated with obesity 
Greatly  
Increased risk 
Moderately 
increased risk 
Low risk 
Insulin resistance  CAD  Ca breast, colon 
endometrium  
Type 2 diabetes 
mellitus  
Hypertension  Polycystic ovarian 
syndrome  
Gall stones 
dyslipidemia  
Osteoarthritis (knee) Impaired fertility  
Breathlessness  Hyperuricemia (gout) Low back ache  
Sleep apnea   Faetal defects with 
maternal obesity  
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Overall cardiovascular risk  
 The degree of risk from diabetes can be categorized with reasonable 
accuracy by taking into account.  
1. The level of blood sugar and the presence of insulin resistance.  
2. The presence of micro and macrovascular complications of diabetes.  
3. The coexistence of other cardiovascular risk factors  
 
The major cardiovascular risk factors indicated in JNC – 7 report are18:   
• Hypertension 
• Smoking  
• Obesity  
• Physical inactivity  
• Diabetes mellitus  
• Dyslipidemia  
• Microalbuminuria or estimated GFR <60ml/mt 
• Age>55 for men >65 for women  
• Family history of premature cardiovascular disease <55 for 
men, <65 for women   
 
 
Metabolic syndrome  
  (or) 
Insulin Resistance. 
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URIC ACID 
 
 Uric acid is the final breakdown product of the PURINE degradation in 
humans. Mammals other than primates oxidize uric acid further to allantoin. It 
is a weak acid with Pka of 5.75 and 10.3. 
 
Purines  
 Nucleic acids (DNA, RNA) which are required for the storage and 
expression of genetic information is made of polynucleotide chain. Nucleotides 
are the building blocks of nucleic acid. These nucleotides are composed of 
purine or a pyramidine base, a pentose monosaccharide and one, two or three 
phosphate groups.  
 Purines are heterocytic nitrogen contain bases whose ring contain both 
carbon and other elements (heteroatoms). The various purine bases are: 
Adenine, Gaunine, Hypoxanthine and Xanthine.  
 Addition of a pentose sugar to a purine base produces a nucleoside. The 
sugar may be ribose or 2-dioxy ribose. Nucleotides are mono, di or tri 
phosphate esters of nucleotides.  
 
Synthesis of purines  
 Humans can synthesize purines from amphibolic intermediates. Purines 
are not dietarily essential. The purines are contributed by 3 sources:  
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 Denovo synthesis  
 Dietary nucleic acids  
 Cellular nucleic acid  
Denovo purine synthesis   
 The atoms of purine ring are contributed by compounds including amino 
acids (aspartic acid, glycine and glutamine), Co2 and derivatives of 
tetrahydrofolate. The purine ring is constructed by 11 step process that results 
in the formation of inosine mono phosphate (IMP). IMP can be converted to 
either adenosine monophosphae (AMP) or guanine mono phosphate (GMP). 
The first step involves synthesis of phosphoribosyl pyrophosphate (PRPP). 
Next step involves synthesis of phosphoribosyl amine from PRPP and 
glutamine and is catalysed by the enzyme amido phosphoribosyl transferase. 
This is the rate limiting step in purine synthesis.  
 
Degradation of purines – production of uric acid  
 The end product of purine catabolism in humans is uric acid. In 
mammals other than higher primates uricase enzyme converts uric acid to a 
water soluble product, allantoin. Humans lack this enzyme.  
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URIC ACID SYNTHESIS FROM PURINES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Uric acid is produced only in liver and small intestine because only these 
two tissues contain the enzyme Xanthine oxidase.  
 
 
AMP GMP 
Adenosine  Guanosine  
Inosine   
Purine nucleoside 
Phosphorylase  
Gaunine   
Hypoxanthine  
Xanthine 
oxidase    
Xanthine  
Xanthine oxidase 
URIC ACID  
Pi  
Pi  
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Salvage pathway for purines 
 All the purines are not degraded to uric acid. Purines that result from 
normal turn over of cellular nucleic acids can be reconverted to nucleotides and 
used by the body. Two enzymes Adenine phosphoribosyl transferase (APRT) 
and Hypoxanthine gaunine phosphoribosyl transferase (HGPRT) are involved. 
Deficiency of HGPRT causes Lesch – Nyhan syndrome.   
Uric acid metabolism  
  The amount of urate in the body is the net result of the amount produced 
and amount excreted. The sources for uric acid are denovo synthesis of purines, 
purines from cellular nucleic acid, and purines from dietary nucleic acid.  
 The total dynamic urate metabolic pool in the body is about 1200mg 
expressed as uric acid of which denovo synthesis contributes about 300-600mg 
and dietary purines contributes about 600-700mg. Each day about 2/3 of the 
uric acid are excreted in the urine and 1/3 is destroyed by bacterial uricolysis in 
the gut.  
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THE TOTAL BODY URATE POOL  
 
 
 
 
 
 
 
 
 
 
 
 Urate anion is freely filtered at the renal glomerulus and kidney handles 
urate by following 
1. Glomerular filtration of 100% of the filtered load 
2. Proximal tubular absorption – of 99% of filtered load.  
3. Tubular secretion of about 50% of filtered load. 
4. Post secretary reabsorption of about 40% of filtered load.  
 
The net clearance of uric acid is around 10% of the filtered load and is in 
the range of 6 to 11 ml / min / 1.73m2.  
Denova synthesis  enovo synthesis  Nucleic acid   
Nucleotides   
Nucleosides  
Bases    
Urate    Tophi     
Urine     Intestine     
Diet      
Salvage 
pathways   
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Plasma urate levels  
 As mentioned urates, the ionized forms of uric acid, predominate in 
plasma extracellular fluid and synovial fluid with approximately 98% existing 
as monosodium urate at pH 7.4. Mono sodium urate is easily dialysed from 
plasma. Binding of urate to plasma proteins has little physiological significance.  
 Plasma is saturated with monosodium urate at a concentration of 415 
µmol/L (6.8 mg/dl) at 37°C. At higher concentrations, plasma is therefore 
supersaturated, creating the potential for urate crystal precipitation. However, 
precipitation sometimes does not occur even at concentrations as high as 4800 
µmol/L (80mg/dl), perhaps because of the presence of solubilizing substances 
in plasma.  
 Plasma urate levels rises at puberty with female values being lower than 
in men until menopause after when it gradually rises to male value. It decreases 
during pregnancy. Hyperuricemia is a characteristic and often an early feature 
of pre-eclampsia.  
 Extrinsic factors, particularly diet, plumbism, the prevalence of high 
ethanol intake in the community and diseases like malaria, thalassemia can 
affect plasma urate distribution in different populations. Epidemiological 
studies show significant variations in plasma urate concentrations between 
different ethnic groups. For example, Polynesians have higher values than 
western Europeans and Americans. This illustrates the genetic, presumably 
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polygenic aspects in the control of serum uric acid. Other epidemiological 
studies emphasize the importance of environmental factors of purine, protein 
and alcohol intake. For example Gress and Zollner (1991) showed that the 
cumulated frequency of plasma urate rose from 6.2mg/dL to about 9.0mg/dL 
between 1962-1971 in association with improved nutritional state of Bovarian 
population.  
 The frequency distribution of plasma urate values based on 
asymptomatic population is only approximately Gaussian, with an excess of 
higher values due to inclusion of some asymptomatic hyperuricaemic subjects. 
Ignoring the slight asymmetry of the frequency distribution and defining 
normality as the mean value ±2SD above the mean, normal upper limit of 
7.0mg/dL (420µmol/dL) for mean and 6.0mg/dL (360µmol/L) for women is 
widely adopted.  
Hyperuricemia  
       Hyperuricemia can result from increased production or decreased 
excretion of uric acid or from a combination of the two processes. When 
sustained hyperuricemia exists, plasma and extracellular fluids are super 
saturated with respect to urate and total body urate is increased.  
 Physiochemically, hyperuricemia is the concentration of the urate in the 
blood that exceeds the solutions limits of monosodium urate in plasma, 415 
mol/l (6.8mg/dl). In epidemiological studies, hyperuricemia is defined as the 
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mean plus 2 standard deviations of values determined from a randomly selected 
healthy population. Hyperuricemia is present between 2.0 and 13.2% of 
ambulatory adults and some what more frequently in hospitalized.  
Classification of hyperuricemia  
Reduced renal excretion  
1. An inherited defect in renal handling of urate.  
2. Renal glomerular disease 
3. Renal tubular dysfunction 
a. Tubulo interstitial nephritis  
b. Competition for tubute excreting mechanism (Lactic acidosis and 
keto acidosis) 
c. Drugs (Diuretics, Pyrazinamide, Ethambutol etc) 
4. Other conditions in which renal tubular dysfunction has been proposed  
a. Hypertension     b. Sickle cell anemia  
c. Myxedema     d. Lead nephropathy  
Increased uric acid production  
1. Dietary sources  
2. Hypoxanthine phosphoribosyl transferase deficiency  
3. Increased phosphoribosyl pyrophosphate activity 
4. Glycogen storage disorders  
5. Hereditary fructose intolerance  
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6. Myeloproliferative diseases  
7. Chronic hemolytic anaemias  
8. Extensive psoriasis  
9. Gauchers disease   
The following abnormalities are commonly associated with but not 
casually related to Hyperuricemia:  
 
i. Obesity  
ii. Dyslipidemia (usually type 4 with increased VLDL and normal 
cholesterol) 
iii. Hypertension  
iv. Insulin resistance  
v. Ischemic heart disease  
 
  These patients may display features of metabolic syndrome.  
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CAUSES OF HYPERURICEMIA IN TYPE 2  
DIABETES MELLITUS 
 
1. DIETARY HABITS: 
 An increase is serum urate level may occur is type 2 DM in various 
situations like purine rich diet such as non vegetarian diets-liver, anchovies, 
kidney, sardines, sweat breads and yeasts. 
2. EXERCISE: 
 Exercise acutely increase serum urate levels by excessive degradation of 
skeletal muscle ATP.  
3. ALCOHOL: 
 Alcohol increases serum urate level by accumulation of organic acids 
(betahydroxy butyrate, acetoacetate, lactate) that compete with the urate for 
tubular secretion and accelerated breakdown of ATP by liver is increased. (Beer 
contains high uric acid) 
4. OBESITY: 
 Various mechanisms play role in increase in serum urate by obesity. 
Like anabolic effects of tissues because of insulin resistance, increase in denovo  
biosynthesis of purines, decreased excretion and increased breakdown. 
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5. DEHYDRATION: 
 Dehydration can impair uric acid excretion by decreased filtration and 
secretion and sometimes with acidosis by competition of H+ ions for excretions. 
Starvation again causes accumulation of organic acids that compete for the 
excretion of urate for tubular secretion. 
SYSTEMIC HYPERTENSION: 
 There are various studies regarding association of systemic hypertension 
with the elevated uric acid level. Probable mechanism suggested is impaired 
excretion of urate because of intrinsic renal defect in hypertension19,20.  
LACTIC ACIDOSIS AND DIABETIC KETO ACIDOSIS: 
 Dehydration and pre renal azotemia both can impair filtration and 
secretion of urate leading to retention and also these may casue diminished 
reabsortion of the uric acid. Again in the setting of acidosis H+ ions compete 
with uric acid leading to enhanced reabsortion and retention.  
HYPER GLYCEMIA: 
 Both uric acid and glucose levels are positively related to body mass 
index. The association of uric acid in relation to glucose reflects the 
biochemical interaction between serum glucose metabolism and purine 
metabolism. 
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RENAL INSUFFICIENCY: 
 Decreased urate filtration contributes to the hyperuricemia of renal 
insufficiency. But the correlation between Bun, serum Creatinine and serum 
uric acid concentration per unit of GFR increases progressively with renal 
insufficiency. The tubular secretory capacity tends to be preserved, the tubular 
reabsorbtive capacity is decreased and extrarenal clearance of uric acid 
increases as the renal damage becomes more severe. 
DRUGS: 
 They mainly act by decreasing the uric acid excretion by competitive 
inhibition of uric acid excretion. Salicytates and nictotinic acid directly compete 
with the urate for tubular secretion. 
 Diuretics, L-dopa, Pyrazinamide, Ethambutol, Cyclosporine decreases 
the secretion of urate in the tubules. 
 
URIC ACID AND INSULIN RESISTANCE 
 
 Nearly 120 years have elapsed since uric acid was first described as a 
potential factor in the development of cardiovascular disease1.  
The actual mechanism of hyperuricemia found in many diabetic patient 
is not known, but different theories have been presented. 
 
 31
 Quiniones (1995) observed that hyperuricemia is a frequent finding in 
insulin resistant states. He found that insulin induces changes in fractional uric 
acid and sodium excretion co related with one another and physiological 
hyperinsulinemia acutely reduces urinary uric acid and sodium excretion in 
coupled patients. They also observed that in insulin resistant individuals 
compensatory hyperinsulinemia imposes a chronic antinatriuretic and anti 
uricosuric pressure on the kidney. 
 Moriwaki (1995) studied the effects of glucose infusion on the renal 
clearances of uric acid, xanthine and oxypurinol and found that the effect was 
not related to osmotic diuresis, but induced by glycosuria / and / or 
hyperglycemia. 
 Muscelli and Coworkers (1996) observed that effect of insulin or urinary 
excretion in normal subjects and found that hyperinsulinemia caused a 
significant decrease in the urinary excretion of uric acid.  
 Tkac I studied 91 type 2 DM patients, 57 patients with myocardial 
infraction were compared with control group of 34 diabetics without clinical or 
electrocardiographic sings of IHD. Higher mean serum uric acid level in 
infarction group was associated with increasing age and serum creatinine levels. 
It was associated with elevated TGL, BMI and hypertension.21. 
 Woo study results found positive association between serum uric acid 
concentration and BMI, with systolic and diastolic BP, urea, creatinine, fasting 
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glucose 2 hour insulin, TGL, apolipoprotein B in men. Similar but fewer 
associations were seen in women with additional positive associations with age. 
The study suggests that serum uric acid may be a marker for the presence of an 
adverse cardiovascular risk profile22. 
 Wannamethee concluded in their study that serum uric acid is not a truly 
independent risk factor for coronary art disease. Increased serum uric acid 
appears to be an integral part of the cluster of risk factors associated with the 
insulin resistance syndrome that include central obesity, increased TG level, 
and serum cholesterol level23. 
 Pearl study concluded high molar equivalent serum antioxidant capacity 
(MESA) between diabetics and non diabetics showed uric acid as a free radical 
scavenger is NIDDM24. 
 They are certain clinical clustering groups with increased cardiovascular 
risk, which have associated hyperuricemia. They are  
1. African American patient group  
2. Patients group with excessive alcohol consumption. 
3. Hypertensive patient groups 
4. Non diabetic patient groups with accelerated arteriosclerosis. 
5. Congestive heart failure patients groups with ischaemic cardiomyopathy. 
6. Metabolic syndrome patients group. 
7. Renal disease patients group and 
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8. Patients group taking diuretics     
Each of the clustering group has metabolic mechanisms that may help to 
explain which serum uric acid may be elevated. 
MECHANISM: 
 Type 2 Diabetes mellitus is strongly associated with hyperuricemia. 
 Potential mechanism involved in the association of hyperuricemia and 
type 2 Diabetes mellitus include the following: 
1. Altered renal sodium handling causes decreases renal blood flow and 
diminishes uric acid excretion  
2. Decreased GFR stimulating urate absorption  
3. Microvascular disease resulting is local tissue ischemia  
4. Ischemia associated with increased lactate production.  
5. Ischemic induces increased xanthine oxidase production. 
Other factors which may contribute are alcohol abuse Lead intoxication, 
obesity, insulin resistance and diuretic use. 
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Mechanism of Hyperuricemia in Hyperinsulinemia 
Hyperinsulinemia 
↓ 
Altered renal  
Sodium handling 
↓ 
↑ Arterial pressure 
↓ renal blood flow 
↓ Uric acid excretion  
↓ 
Hyperuricemia  
(Adapted from ward, Lancet 1998) 
Increased serum uric acid has been found to predict the development of 
renal insufficiency in individuals with normal function20. 
In type 2 Diabetes mellitus hyperuricemia seems to be associated with 
metabolic syndrome and with early onset or increased progression to overt 
nephropathy, whereas hyperuricemia was associated with hyper filtration and a 
later onset or decreased progression to overt nephropathy25. 
Hyperuricemia has been associated with increasing Body mass index 
(BMI). The role of leptin is possibly being a regulator of serum uric acid level 
in humans26. 
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From the review the following conclusion was arrived:        
 Determining the truth in medical science is a difficult business.       
Serum uric acid may or may not be an independent risk factor because its 
linkage to other risk factors is so strong. However there is not much correlation 
regarding its role as a marker or risk factor that is clinically significant and 
relevant. 
Hyperuricemia should alert the clinician to an overall increased risk of 
cardiovascular disease. Elevations of uric acid > 4 mg/dl should be considered a 
“Red flag” in those patients at risk for cardiovascular diseases and should alert 
the clinician to strive and utilize a global risk reduction programme to reduce 
the complications of atherogenic process. 
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MATERIALS AND METHODS 
 
Setting     : Government Rajaji Hospital and  
      Madurai Medical College, Madurai  
Collaborative Department  : Department of Biochemistry,  
      Madurai Medical College, Madurai 
Study Design   : Descriptive analytical study 
Period of study    : January 2005 to February 2006 
Sample size     : 70 cases  
Ethical committee approval  : The present project was approved by 
      the Ethical committee  
Inclusion criteria   
1. Patients with type 2 diabetes mellitus (patients were taken 
irrespective of their glycemic control and their duration of diabetes)   
2. Patients who were above 40 years were included  
3. Both sexes were included 
Exclusion criteria  
1. Patients with renal failure  
2. Pregnancy and lactating mothers. 
3. Patients who were on long term diuretics and steroid. 
4. Patients who were regularly consuming  alcohol   
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5. Patients who were on anti metabolite and chemotherapy drugs 
6. Patients who had hepatic and metabolic disorders.   
7. Patients who had PVD / CVA / Pulmonary tuberculosis. 
8. Renal transplant patients. 
Controls  
 Subjects who were above 40 years and had normal blood sugar and who 
met the above exclusion criteria. 
Consent  
   The study group thus identified by the above criteria (inclusion and 
exclusion) were first instructed about the nature of study. Willing participants 
were taken up after getting a written informed consent from them.  
Materials  
 Thus a total of 70 cases who satisfied the inclusion and exclusion criteria 
above were taken up for subsequent study. 30 age and sex matched subjects 
were kept as control.  
Conflict of interest  
 There was no conflict of interest. 
Financial support  
 Nil   
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Limitations  
1. Because of limited resources GTT, Hb A1c, leptin level, C peptide assay, 
plasma insulin assay could not be tested. 
2. Xray chest was not performed in every case due to technical limitation.  
3. Only serum uric acid levels were analysed, urinary excretion and urate 
clearance was not done.  
 
Methods  
 Selected socio-demographic, clinical, laboratory data were elicited from 
the patients and controls and recorded in proforma. 
1. Socio demographic data  
 Age  
 Sex  
2. Clinical data  
 Body weight  
 Height  
 BMI, waist hip ratio (WHR) 
 Systolic diastolic blood pressure  
 Cardiovascular risk factors  
 Clinical examination   
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3. Laboratory data  
 Blood urea estimation was done manually by using diacetyl 
monoxime method (DAM). 
 Serum creatinine estimation was done by using COBAS auto 
analyzer.  
 Serum uric acid was done by using semi auto analyzer. 
Principle  
 Uric acid is converted by uricase to allantoin and hydrogen peroxide in 
the presence of peroxidase (POD) oxidiz`es the chromogen to a red coloured 
compound which is read at 500mm.  
        Uricase  
 Uric acid +2H2O+O2   Allantoin +Co2+H2O2 
 
              DHBS POD 
 2H2O2+4aminophyrine +            Red quinolone + 
 H2O+Hcl (DHBS 3, 5 – Dichloro – 2 hydroxy benzene sulphonic acid)  
 
Statistical analysis  
 Data was entered in Microsoft excel spread sheet and analysed 
statistically using standard statistical software. Student ‘t’ values was applied 
for significance. Significance was considered, if the ‘p’ value was below 0.05. 
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DEFINITIONS USED IN THE PRESENT STUDY 
 
1. Diabetes mellitus  
 Criteria for the diagnosis diabetes mellitus (modified form of American 
Diabetes Association, 2004)4. 
1. Symptoms of diabetes + (R) blood glucose ≥200mg/dL 
2. Fasting plasma glucose ≥126mg/dL 
3. Two hour plasma glucose (postprandial) ≥200mg/dL during an oral 
glucose tolerance test  
2. Hyperuricemia  
  Hyperuricemia is defined as serum uric acid level ≥8mg/dL in males and 
≥6mg/dL in females4.  
3. Body mass index  
 It is estimated by using the following formula: weight (kg)/ height2 (m) 
4. Obesity  
 Obesity is usually defined as body mass index >30, body mass index 
between 25 to 30 is known as overweight. Body mass index between 25 to 30 
should be viewed as medically significant, especially in the presence of other 
risk factors like hypertension, diabetes. Large scale epidemiological studies 
suggest that cardiovascular morbidity begins to rise when body mass index     ≥
25, suggesting that the cut off for obesity should be lowered.  
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Waist hip ratio  
 The waist is measured by taking a circumference that gives the narrowest 
measurement between the ribcage and the iliac crest. The hip measurement is 
taken by measuring at a level that gives the maximal measurement of hip over 
the buttocks. It is a simple, and convenient measurement that is unrelated to 
height, correlates closely with body mass index and waist hip ratio is an 
approximate index of intra abdominal fat mass and total body fat.  
 Waist hip ratio >0.9 in women and >1.0 in men being abnormal. 
 
Conversion of blood glucose to plasma glucose:  
 John Neale (1999) described the conversion of blood glucose to plasma 
glucose by using this formula:  
 Plasma glucose = whole blood glucose × 1.12   
 
 
 
 
  
    
 
RESULTS 
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The total number of subjects included in this study was 100. Among 
those 100 subjects, 70 were cases (type 2 Diabetes mellitus) and 30 were 
controls (Non Diabetic). 
 
Table 8: Introduction  
 CASES CONTROLS 
Total No 70 30 
Gender M = 46 F = 24 M = 18 F = 12 
Age (years) 41 to 75 43 to 73 
Mean Age (years) 60 56 
BMI 19.4-29.2 18.4-26.0 
WHR 0.76-1.14 0.76-1.10 
FBS (mg/dl) 128-196 84-122 
PPBS (mg/dl) 154-323 136-184 
SUA (mg/dl) 3.0 to 8.1 2.7 to 5.5 
 
 
 
Analysis of cases and controls with respect to age: 
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The age of the subjects in the study group ranged from 41 to 75 years. 
The mean and standard deviation for age of the cases and controls were 60.1+ 
8.82 and 56.27 + 7.84 respectively, there was no significant difference among 
the cases and controls with reference to the age. The distribution of cases and 
controls in relation to age is provided in table 9 given below:  
 
Table 9: Cases and controls in relation to age 
 
 
Cases* Controls Age group 
No % No % 
40-50 11 15.7 8 26.7 
51-60 23 32.9 12 40.0 
61-70 27 38.6 9 30.0 
71-80 9 12.8 1 3.3 
Mean 60.01 56.27 
S.D 8.82 7.84 
 
*p= 0.0529 (not significant) 
 
 
 
Analysis of cases and controls with respect to gender:   
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Among 70 cases studied, there were 46 males and 24 females. Among 
30controls there were 18 males and 12 females. The details are given in      
table 10 provided below:  
 
TABLE: 10 Cases and Controls in relation to gender  
 CASES* CONTROLS 
Sex No % No % 
Male 46 65.7 18 60 
Female 24 34.3 12 40 
Total 70 100 30 100 
 
*p = 0.7503 (not significant) 
 The sex composition of the study group and control group does not differ 
significantly.  
 
 
 
 
 
Analysis of cases and controls with respect to B.M.I:  
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 Among 70 cases and 30 controls screened for BMI, non were obese.  The 
mean and standard deviation for BMI of the cases and controls were 24.1 + 2.98 
and 21.6 + 2.3 respectively. The details are shown in table 11 given below: 
  
Table: 11 Cases and control with respect to BMI  
 CASES* CONTROLS 
BMI No % No % 
<25 38 52.9 26 66.7 
>25 32 47.1 4 33.33 
Total 70 100 30 100 
Mean 24.1 21.6 
S.D 2.98 2.3 
 
*p = 0.0002 (significant) 
The BMI of the study group was significantly higher than that of the 
control group.   
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Blood sugar distribution among cases: 
  
The details of fasting and post prandial blood sugar  distribution among 
the cases are shown in the table 12 given below:  
 
Table: 12 (F) BS and (PP) BS among cases  
Bl sugar Mean S.D 
(F) BS 144.28 38.21 
(pp) BS 212.01 42.13 
      
 
The Mean and Standard deviation for fasting blood sugar was 144.28 + 
38.21 similarly for post prandial blood sugar was 212.01 ± 42.13 among 
diabetics. Thus showing that their diabetic status was under poor control.  
 
 
 
 
 
 
Distribution of Cases and Controls In Relation to Selected 
Cardiovascular Risk Factors  
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Analysis of cases and controls in relation to selected cardiovascular risk 
factors are provided in Table 13 given below. 
 
Table 13: Selected Cardiovascular risk factors  
 
CASES CONTROLS 
Risk factor 
No % No % 
Family history 
Yes* 
No 
 
17 
53 
 
24.3 
75.7 
 
5 
25 
 
16.7 
83.3 
*p VALUE 0.5622 ( Not Significant ) 
Smoking among 
males  
Yes**  
No 
 
 
18 
28 
 
 
40 
60 
 
 
5 
13 
 
 
27.8 
72.2 
**p VALUE 0.5746( Not Significant ) 
Hypertension  
Yes *** 
No 
 
15 
55 
 
21.4 
78.6 
 
4 
26 
 
13.3 
86.7 
***p VALUE 0.5044 ( Not Significant ) 
 
There was no significant difference between cases and controls in 
relation to selected cardiovascular risk factors.   
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Distribution of cases and controls in relation to serum uric acid Level 
(SUA):  
Serum uric acid in the study population and control varied from 3.0 to 
8.1 and 2.7 to 5.5 mg/dl respectively. The mean and standard deviation of uric 
acid among cases was 5.08 + 1.42 while in control it was 3.55 + 0.62 
respectively.  
 
The details are shown in the table 14 given below:  
 
Table 14: Serum Uric Acid level in diabetics and controls 
 
Cases Controls 
Mean S.D Mean S.D 
 
Serum uric 
acid* 5.08 1.42 3.55 0.62 
 
*p value : 0.0001 (significant) 
 
The serum uric acid level of diabetics was very much elevated compare 
with controls and it was highly significant. 
 
 
 
 49
 
Analysis of Hyperuricemia in cases and controls 
 
Hyperuricemia is defined as SUA level ≥8mg/dL in males and  ≥6mg/dL 
in females. 7 cases had hyperuricemia while none in controls. The results are 
displayed in table 15 given below:  
 
Table 15:   Hyperuricemia in cases and controls 
Cases Controls  
Hyperuricemia No % Mean S.D No % Mean S.D 
+* 7 10 7.54 0.5 0 - - - 
- 63 90 4.81 1.21 30 100 3.55 0.62 
 
*p value = 0.0001 (significant) 
 
 This table clearly shows that the prevalence of hyperuricemia more in 
diabetic patients when compared to controls. 
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Analysis of Gender distribution with serum uric acid among the cases  
 
The mean value of serum uric acid was 4.77±1.4 in males and 5.68±1.3 
in females and details are given table 16 below. 
 
Table 16: Serum uric acid values in relation to gender among cases   
 
Sex No Mean S.D p value 
Male 46 4.77 1.4 
Female* 24 5.68 1.3 
0.0196 
 
*
 p value = 0.0196 (significant) 
 
In the study group mean uric acid values were higher in females than 
males and the difference was statistically significant.  
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Serum uric acid value in relation to BMI in cases 
 
 The mean value of serum uric acid was 6.35±0.82 in those with 
BMI>25, it was significantly higher when compared to those having BMI<25. 
The mean value of serum uric acid in BMI < 25 was 4.01±0.81. 
 
 The details are shown in table 17 given below:  
 
Table 17: Uric acid with regard to BMI among cases   
BMI No Mean S.D 
< 25 38 4.01 0.81 
> 25* 32 6.35 0.82 
 
*p value = 0.0001 (significant) 
 
Mean uric acid level was positively correlated with BMI 
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Serum uric acid value in relation to waist hip ratio (WHR) 
 
 Uric acid level increases with increasing WHR. The WHR abnormality 
was considered in 36 cases based on, WHR as 1.0 and above for men, 0.90 and 
above for women and correlated with uric acid level, it was significant. The 
details are shown in table 18 given below. 
 
 
Table 18: Waist hip ratio and Hyperuricemia   
 
WHR abnormality No Mean S.D 
Yes * 36 6.12 0.72 
No 34 3.97 0.43 
 
 
*p value = 0.0001 (significant) 
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Smoking and serum uric acid among the cases (only in males) 
  
The mean value of serum uric acid level was slightly higher among 
smokers 4.80±1.12 when compared to non smokers 4.56±1.06, but the 
difference was not significant statistically. This is shown in table 19 given 
below:   
 
Table 19: Uric acid values in relation to smoking (only in males)   
 
Smoking No Mean S.D 
Yes* 18 4.80 1.12 
No 28 4.56 1.06 
 
*p value = 1.5472 (not significant) 
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Serum uric acid values in hypertensive patients  
 
 The mean serum uric acid level in the hypertensive group (6.15±0.92) 
was significant more than non hypertensive group (5.15±1.40) in the cases and 
the results are shown in the table 20 given below:  
 
Table 20:  Serum uric acid values in relation to hypertension 
 
HT No Mean S.D 
Yes* 15 6.15 0.92 
No 55 4.79 1.4 
 
*p value = 0.0001 (significant) 
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Serum uric acid level in relation to lipid profile abnormality  
 
 
 The mean serum uric acid level in patients with lipid profile abnormality 
was 6.49±0.85, while it was 4.52±1.20 in patients without lipid profile 
abnormality, and it was highly significant. The results are shown in table 21 
given below.  
 
Table 21: Serum uric acid value in relation to lipid profile abnormality:  
Lipid profile 
abnormality 
No Mean S.D 
Yes* 20 6.49 0.85 
No 50 4.52 1.2 
 
*p value = 0.001(significant) 
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Table 22: CAD and Hyperuricemia  
 
Type of CAD No of Patients 
Total no of 
hyperuricemia 
Sex % 
Ischemia 10 2 IM + IF 20 % 
Infarction 5 3 0 M + 3F 60% 
 
 This table was showing number of patients with ischemia – 10  
 Of these only 2 had hyperuricemia with equal sex distribution (1:1) 
 Number of patients with infarction was 5 
 Of these only 3 had hyperuricemia, all are female patients (0:3) 
 
 Percentage of hyperuricemia in infarction is higher than in ischemia, and 
female patients were more involved in CAD than males in relation to 
hyperuricemia.  
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Serum uric acid value in relation to duration of diabetes  
 
 Mean value of serum uric acid level was higher in longer duration (8-12 
years) of diabetes 6.34±0.84, when compared to shorter duration (2-4years) of 
diabetes 3.88±0.93.  
 
 This is shown in table 23 given below:  
 
Table 23: Duration of Diabetes and Hyperuricemia 
DOD No Mean S.D 
2-4 yrs 13 3.88 0.93 
4-8 years 34 4.69 1.27 
8-12 years* 23 6.34 0.84 
 
*p value = 0.001 Significant 
 
Uric acid level increases with increasing duration of diabetes and it was 
statistically significant.  
 
DISCUSSION 
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 Diabetes is the most common risk factor for cardiovascular disease, and 
it is present in nearly 25% adults and increases in prevalence with age.  
 Hyperuricemia is one of the component of metabolic syndrome2. “In the 
absence of gout the presence of hyperuricemia in patients with type 2 diabetes 
mellitus is an important marker as well as an added risk factor for 
atherosclerosis”. 
 In this study the relation between serum uric acid level and diabetes was 
examined. Uric acid is a marker for CAD in combination with other risk factors 
among diabetics.  
 Though uric acid level and age was independent, it is possible that 
duration of the illness may have an impact on uric acid levels.  
 In the present study females have higher uric acid level when compared 
to males. The mean uric acid value in males 4.71±1.4 while in females it was 
5.68±1.3, and the difference was statistically significant in this study. The 
possible reasons for such difference may be attributable to increased BMI and 
increased WHR among women.  
 In the present study serum uric acid correlated well with body mass 
index (BMI). The mean uric acid in those subjects with BMI>25 were higher 
than those with BMI < 25 (6.35±0.82 Vs 4.01±0.81) and the difference was 
statistically significant27,28.   
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 Rathman (1997) assessed the various components of insulin resistance 
syndrome in young black and white adults. They concluded body mass index 
showed strongest positive correlation with the uric acid among insulin 
resistance components29.    
 Waist hip ratio is an important measure of obesity, especially central 
obesity. Intra abdominal fat has significant implication for morbidity than 
subcutaneous fat present in buttocks and extremities.   
 Abdominal obesity is a component of metabolic syndrome2. Abdominal 
obesity >102cm in men and >88cm in women is abnormal. In this study patient 
with higher waist hip ratio has higher uric acid level when compared with low 
waist hip ratio. 
 The mean uric acid value in patients with waist hip ratio abnormality and 
patients without waist hip ratio abnormality was 6.12±0.72 and 3.97±0.43 
respectively and the difference was statistically significant. 
 Strong epidemiologic data have linked serum uric acid to hypertension in 
humans19 and experimental animal data suggests hyperuricemia causes 
hypertension30,31. The Olivetti heart study had shown a independent positive 
association between serum uric acid and development of hypertension32.  
 When the level of serum uric acid in hypertensive patients was compared 
with non hypertensive patients in cases, the difference was significantly higher 
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in the present study. The present observation on uric acid among diabetic 
hypertensives is in consistent with other studies. 
 Elevated triglycerides which is the most important risk factor in 
acceleration of atherosclerosis21. There is a significant relationship between 
serum uric acid and dyslipidemia33. In the present study dyslipidemia was 
noticed as a risk factor in those with CAD, Who had significantly elevated 
serum uric acid levels.  
“Uric acid stabilizes the platelet aggregation and enhances thrombotic 
tendency”, thus suggested hyperuricemia as a strong predictor of myocardial 
infarction and stroke and all causes of mortality. 
 Patients with poor metabolic control and longer duration of diabetes 
were more susceptible to develop various complications including 
hyperuricemia as observed in the present study. Our study also shows that 
higher level of serum uric acid was seen in patients with longer duration of 
diabetes when compared with shorter duration of diabetes. This difference was 
statistically significant.  
 Uric acid >4mg/dL should be considered as a “Red flag” in those 
patients at risk for cardiovascular disease. In this study 74.3% of diabetic 
patients have serum uric acid level >4mg/dL, while only 23.3% of the control 
have serum uric acid >4mg/dL. In these patients the clinician should strive to 
utilize global risk reduction Programme to reduce the complications of 
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atherogenic process. The details in relation to this study is shown in the table 25 
given below: 
 
Table 24:  Cases and controls in relation to uric acid 
Cases  Controls  Serum Uric 
Acid  No.  Percentage  No. Percentage  
<4mg 18 25.7 23 76.7 
>4mg 52 74.3 7 23.3 
p value = 0.0001 significant  
 
 The association of serum uric acid with cardiovascular disease has been 
appreciated for nearly half a century1. However, it role as a cardiovascular risk 
factor remains controversial. The Framingham heart study concluded that uric 
acid does not have a causal role in the development of coronary artery disease 
and death from cardiovascular disease. In an epidemiologic follow up study an 
association between serum uric acid and cardiovascular disease was shown. The 
recent PIUMA study also concluded that raised serum uric acid is a powerful 
risk marker for subsequent cardiovascular disease and all cause mortality34. 
 Of the 70 cases of type 2 diabetes mellitus serum uric acid was elevated 
in 7 patients which accounts for 10% of cases. Canon showed a prevalence of 
hyperuricemia in 25% of longstanding uncontrolled diabetes. But in this study 
many of the cases were on treatment which might have affected the results.  
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  A large Body of evidence links uric acid with metabolic syndrome of 
insulin resistance, obesity, hypertension, and dyslipidemia. In this study 
relationship between obesity, hypertension, dyslipidemia and hyperuricemia 
was statistically significant.  
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CONCLUSION 
 
 Uric acid was significantly elevated in diabetic population. 
 
 The serum uric acid level was independent of age and smoking status 
in males. 
 
 Significant correlation was noticed between serum uric acid and BMI 
as well as WHR.  
 
 Significant elevation of uric acid level was observed more among 
females. 
 
 Elevated uric acid levels were significantly noticed among those with 
hypertension, dyslipidemia, coronary artery disease and chronicity of 
the diabetes. 
 
 Uric acid level above 4mg/dl in diabetic population (considered as a 
“Red flag” sign) was a marker or risk factor for CAD, which was 
present in 70% of study population. 
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RECOMMENDATIONS / SUGGESTIONS 
  
Routine annual estimation of uric acid among diabetics from the 
identification of diabetes will help the clinician to find out the changing trends 
of uric acid level which is likely to be influenced by control of blood sugar and 
development of hypertension, such cases should be carefully monitored for 
CAD as well as other vascular episodes. 
 
 Since uric acid is a confounding factor and multiple factors are involved 
for elevated uric acid. A meticulous control of blood sugar, hypertension, 
dyslipidemia among diabetics will bring down elevated uric acid level in 
diabetics. 
 
 Let us have a moto of  
 
   “Asses diabetics for risk factors, 
    Assist to control them and  
    Arrest the development of complications” 
 
 With the pharmacological and non pharmacological means. 
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SUMMARY 
 
Diabetes mellitus is strongly associated with hyperuricemia. The role of 
uric acid is a independent risk factor for cardiovascular disease is a matter of 
controversy. The present study was proposed to asses the uric acid status in 
patients with diabetes mellitus and to find out its association with age, gender, 
BMI, WHR, smoking and CAD. With rigid criteria, patients were selected 
carefully and evaluated on social, clinical, and laboratory aspects after getting 
institutional, ethical clearance and informed consent. 30 healthy age, sex 
matched individuals were kept as control. There were 46 males and 24 Females 
in the study group and 18 males  and 12 females in the control group. The mean 
and standard deviation of age among the patient group was 60.01± 8.82 and  
56.27 ± 7.84 in control group. There was no significant difference among cases 
and controls in relation to age. 
 In study group, BMI below 25 seen in 32 cases (45.7%) BMI above 25 
seen in 38 cases (54.3%) which was significantly more than controls. BMI had 
significantly correlated with hyperuricemia. Similarly WHR was greater among 
women than men in diabetics, which also correlated with elevated serum uric 
acid significantly. 
 Elevated serum uric acid level was noticed more among those who had 
hypertension (21.4%), dyslipidemia (28.6%), Coronary artery disease (21.4%) 
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and they were significant. Patients with longer duration of diabetes also had 
elevated uric acid level. 
The factors contribute to hyperuricemia in diabetes are  
1. Hyperinsulinemia acutely reduces urinary uric acid and sodium 
excretion. 
2. Hyperinsulinemia imposes a chronic antinatriuretic and antiuricosuric 
pressure on the kidney. 
3. Microvascular disease in diabetes mellitus causes local tissue ischemia, 
and decreased renal blood flow. Ischemia with associated lactate 
production that blocks urate secretion in proximal tubules. Increased uric 
acid synthesis due to increased purine metabolism, ischemia induced 
increased xanthine oxidase production, insulin resistance, and diuretic 
use. 
 Meticulous control of blood sugar, hypertension, dyslipidemia, body 
weight and abdominal girth, form an essential component of diabetes which 
will bring down uric acid level, a less discussed issue among diabetic 
population. 
In view that it is worth to explore uric acid levels atleast in patients with 
family history of diabetes and in obese diabetic patients to detect early 
cardiovascular complications.  
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SERUM URIC ACID LEVEL IN TYPE 2  
DIABETES MELLITUS 
Name:    
Age:    Sex:  M/F  
Ip No:    Ward:   
Duration of Diabetes: BMI:  WHR: 
Symptoms:  
Polyuria, Polydypsia, Polyphagia    
Chest pain,                       Pedal edema  
Breathlessness   Headache    Vomiting  
Fever     Numbness, Paraesthesia  
Personal / Family history:  
Smoking   Family history   
Alcohol    Chronic drug intake  
Clinically: 
 Hypertension :  Bp: / mmHg  
 Obesity  :  BMI  
 Retinopathy  : 
 Neuropathy  : 
 IHD   : 
 Stroke/ TIA  : 
PVD   : 
 
Investigations: 
Urine alb     :  Sug:   Dep:  
Usg abd    : 
ECG     : 
ECHO    : 
Lipid profile abnormality  :  
Renal parameters (urea, creatinine):  
Bl. Sugar (F)   : 
Bl. Sugar (PP)  : 
Sr. Uric acid   :  
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Master Chart  
S.No Age Sex DOD BMI WHR Smoking
Family 
History 
of 
Diabetes
Systemic 
Hyper 
Tension
IHD BS(F) BS (PP) Renal Parameters USG Abd
ECHO/EC
G IHD
Lipid Profile 
abnormality
Retino 
pathy
Neuro 
pathy
Sr.Uric 
acid
1 54 M 6 20.6 0.83 N Y N N N N 92 116 N N N N N 2.7
2 46 M 3 19.4 0.8 N N N N N N 78 126 N N N N N 4.2
3 62 M 8 20.3 0.81 N Y N N N N 106 148 N N N N N 2.9
4 64 M 10 25.4 0.84 N N Y N N N 126 147 N N N N N 3
5 43 F 2 18.6 0.78 N N N N N N 110 167 N N N N N 3.6
6 59 F 7 21.4 0.82 N N N N N N 120 172 N N N N N 4.5
7 67 M 8 22.4 1.1 N N Y N N N 130 161 N N N N N 5.5
8 52 M 3 20.6 0.81 N N N N N N 121 147 N N N N N 3.2
9 63 M 8 24.7 0.88 N N N N N N 120 162 N N N N N 3.7
10 60 F 4 23.8 0.87 N N N N N N 110 128 N N N N N 3.8
11 55 F 3 21.7 0.8 N N N N N N 144 168 N N N N N 4.2
12 49 F 3 19.6 0.78 N N N N N N 133 167 N N N N N 4
13 44 M 3 18.4 0.82 N N N N N N 128 149 N N N N N 2.8
14 55 M 6 20.4 0.83 N N N N N N 112 160 N N N N N 3.2
15 57 M 7 21.2 0.84 Y N N N N N 113 163 N N N N N 3.9
16 62 M 5 26 1.02 N Y N N N N 140 172 N N N N N 4.3
17 67 F 7 24.3 0.9 N N Y N N N 106 128 N N N N N 2.9
18 49 F 2 20.6 0.84 N N N N N N 112 142 N N N N N 3
19 51 F 3 21.4 0.86 N N N N N N 119 167 N N N N N 3.7
20 55 M 3 20.8 0.8 N N N N N N 106 143 N N N N N 3.8
21 66 F 10 25.8 0.87 N N N N N N 111 132 N N N N N 3.4
22 62 M 9 23.2 0.83 N N N N N N 107 167 N N N N N 4
23 64 M 8 23.6 0.82 Y Y N N N N 121 148 N N N N N 3.8
24 47 M 2 20 0.84 N Y N N N N 110 151 N N N N N 2.7
25 53 F 6 19.6 0.76 N N N N N N 122 170 N N N N N 3.3
26 57 F 5 20.3 0.8 N N N N N N 96 130 N N N N N 3.1
27 48 M 2 20.4 0.81 Y N N N N N 98 127 N N N N N 3.2
28 45 M 2 19.6 0.8 N N N N N N 102 118 N N N N N 3.7
29 59 F 7 18.4 0.8 N N N N N N 100 128 N N N N N 3.1
30 73 M 8 25.6 1.08 Y N Y N N N 126 170 N N N N N 3.4
CONTROLS MASTER CHART
S.No Age sex DOD BMI WHR Smoking
Family 
History of 
Diabetes
Systemic 
Hyper 
Tension
IHD BS (F) BS (PP) Renal Parameters
USG 
Abd
ECHO
/ECG
Lipid Profile 
abnormality
Retino 
pathy
Neuro 
pathy
Sr.Uric 
acid
1 52 M 6 20.6 0.86 N N N N 192 222 N N N N N N 4.2
2 69 M 10 25.8 1.08 Y Y Y Y 143 213 N N I Y Y N 5.9
3 41 M 2 19.7 0.76 N N N N 130 196 N N N N N N 3.1
4 55 M 5 20.2 0.8 N N N N 113 173 N N N N N N 3.8
5 62 M 8 28.8 1.12 Y N N N 196 243 N N N Y N N 8.0
6 51 M 3 21.9 0.86 N N N N 115 173 N N N N N N 4.6
7 61 M 7 23.2 0.8 Y N N N 126 200 N N N N 4.8 3.7 3.5
8 47 M 3 20.4 0.78 N Y N N 108 187 N N N N N N 3.7
9 62 M 6 23.7 0.84 N N N N 192 273 N N N N Y N 4.8
10 44 M 4 23.3 0.83 N N N N 184 192 N N N N N N 4
11 71 F 12 25.7 0.91 N N Y Y 192 212 N N I Y Y Y 5.9
12 59 F 9 25.3 0.89 N Y N N 113 170 N N N N N N 5.3
13 75 F 14 27.4 0.93 N N Y N 215 233 N N N Y Y N 5.9
14 53 M 4 21.4 0.8 Y N N Y 214 222 N N N N N N 3
15 67 M 4 22.6 0.83 N N N N 223 245 N N N N N N 3.7
16 77 M 10 25.8 0.97 Y N Y Y 147 192 N N I Y Y N 6.4
17 60 F 8 26.9 0.94 N N N YES 248 291 N N MI N N N 7.9
18 47 M 5 20.2 0.8 N N N N 143 175 N N N N N N 3.8
19 55 F 7 24.8 0.84 N Y N N 132 165 N N N N N N 4
20 66 F 10 26.3 0.92 N N N N 130 145 N N N Y Y N 5.8
21 42 M 2 19.4 0.76 N N N N 148 192 N N N N N N 3.8
22 67 M 7 20.4 0.8 Y N N N 157 211 N N N N N N 4.6
23 63 M 9 25.4 0.82 Y N N N 215 253 N N N N N N 5.8
24 73 F 12 27.2 0.92 N N Y N 205 261 N N N Y Y N 5.9
25 59 M 10 27.4 1.14 Y Y Y Y 196 243 N N I Y N N 8.1
26 57 F 6 23.2 0.81 N N N N 163 174 N N N N N N 4.6
27 62 F 6 24.5 0.92 N N N N 105 126 N N N N N N 4
28 63 M 7 25.2 1.02 Y N Y Y 175 233 N N MI N N N 6.5
29 60 F 10 27.4 1.12 N Y N N 196 221 N N N N Y N 5.8
30 58 F 9 27.2 1.1 N N N N 144 216 N N N Y N N 5.7
31 61 M 7 20.4 0.8 Y N N N 224 247 N N N N N N 3.2
32 63 M 8 22.3 0.84 N N N N 143 196 N N N N N N 4.6
CASES MASTER CHART
33 69 M 10 25.4 1.02 N Y Y Y 132 176 N N I Y Y N 6.7
34 65 M 6 24.7 0.99 Y N N N 149 191 N N N N N N 5.6
35 53 M 3 22.3 0.84 N N N N 283 263 N N N N N N 5
36 54 M 6 23 0.86 N N N N 240 271 N N N N N N 4.8
37 67 F 12 28.6 1.08 N Y YES YES 211 243 N N MI YES YES N 6.7
38 63 M 7 25.9 1.02 N N N N 187 211 N N N N N N 6.8
39 66 F 6 25.8 1 N Y N N 143 209 N N N N N N 5.4
40 61 M 6 23.8 0.88 N N N N 173 231 N N N N N N 3
41 62 M 6 20.8 0.8 Y N N N 143 199 N N N N N N 3.1
42 72 M 10 25.8 0.92 N Y Y Y 145 211 N N I Y Y Y 6.7
43 57 M 7 20.2 0.8 N N N N 127 192 N N N N N N 3.2
44 44 M 4 20 0.8 N N N N 108 142 N N N N N N 3
45 76 F 14 29.2 1.08 N N N Y 227 265 N N I Y N Y 7.7
46 54 M 7 25.4 0.92 N Y N N 191 211 N N N N N N 5.2
47 63 M 7 25.8 0.88 N N N N 219 248 N N N Y N N 5.8
48 57 M 6 20.1 0.8 N N N N 119 187 N N N N N N 3.6
49 67 M 10 26.7 0.96 Y N N Y 129 147 N N MI N N N 6.6
50 69 M 12 27.8 1 N N Y N 136 191 N N N Y Y N 6.8
51 59 M 9 21.3 0.78 N N N N 286 323 N N N N N N 4.6
52 73 M 10 25.6 0.92 N Y Y N 215 223 N N N Y N Y 6.6
53 48 M 3 23.2 0.82 Y N N N 207 219 N N N N N N 4.2
54 57 F 7 26.8 0.88 N N N N 126 200 N N N Y N N 4.8
55 69 F 10 27.8 0.96 N Y N YES 247 261 N N MI YES YES N 7.9
56 52 F 5 25 0.9 N N N N 145 203 N N N N N N 4.2
57 48 F 6 21.2 0.8 N N Y N 192 196 N N N N N N 3.3
58 47 M 5 20.6 0.78 Y N N N 183 180 N N N N N N 3.1
59 62 M 7 25.4 1.07 N N N Y 273 322 N N I N N N 6.3
60 55 M 3 23.2 0.92 Y N N N 250 271 N N N N N N 4.7
61 65 M 8 25.8 1.02 N Y N N 160 178 N N N N Y N 6
62 63 F 7 20.4 0.8 N N N N 185 213 N N N N N N 4.2
63 76 F 14 29.2 1.09 N Y Y Y 192 261 N N I Y Y Y 5.9
64 51 F 3 23.1 0.84 N N N N 193 199 N N N N N N 5.8
65 50 F 6 21.4 0.87 N N N N 143 173 N N N N N Y 5.5
66 57 M 3 19.6 0.78 Y N N N 113 161 N N N N N N 2.8
67 49 M 3 20.1 0.81 Y N N N 105 122 N N N N N N 3
68 73 F 12 28.4 1.09 N Y N Y 241 283 N N N Y Y Y 8.1
69 59 M 7 24.7 1.06 N N N N 139 171 N N N N N N 4.9
70 67 F 12 29.3 1.08 N Y Y Y 149 199 N N I N Y N 5.9
DOD - Duration of Diabetes
N - Normal
Y - Yes
I - Ischemia
MI - Myocardial infarction
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FIG :1 
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HYPERURICEMIA IN CASES & 
CONTROLS
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FIG:3
SERUM URIC ACID LEVEL AND BMI
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FIG: 6
DISTRIBUTION OF CASES AND CONTROLS 
ACCORDING TO SERUM URIC ACID LEVELS
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FIG:4
DURATION OF DIABETES AND 
HYPERURICEMIA
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FIG :5
WAIST HIP RATIO AND
HYPERURICEMIA
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